Controlled release antibiotics for dry powder lung delivery

Drug Development and Industrial Pharmacy

Volumn 36, Issue 1, 2010, Pages 119-126

  Adi, Handoko ^a   Young, Paul Michael ^a   Chan, Hak Kim ^a   Salama, Rania ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibiotics; Ciprofloxacin hydrochloride; Controlled release; Doxycycline hydrochloride; Dry powder inhaler; Polyvinyl alcohol

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; POLYVINYL ALCOHOL;

AEROSOL; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRY POWDER; MORPHOLOGY; PARTICLE SIZE; SPRAY DRYING; TEMPERATURE;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; DOXYCYCLINE; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; LUNG; MICROSPHERES; PARTICLE SIZE; POLYVINYL ALCOHOL; POWDERS; TIME FACTORS;

EID: 74949121129     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903099769     Document Type: Article

References (35)

1. Kulczycki LL, Murphy TM, Bellanti JA. (1978). Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA, 240(1): 30-34
2. Nicotra MB. (1994). Bronchiectasis. Semin Respir Infect, 9(1):31-40.
3. Trucksis M, Swartz MN. (1991). Bronchiectasis: A current view. Curr Clin Top Infect Dis, 11:170-205.
4. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE. (1996). Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks. Thorax, 51(4):364-368
5. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. (1993). Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med, 328(24):1740-1746
6. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. (1999). Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. N Engl J Med, 340(1):23-30.
7. Hodson ME, Penketh AR, Batten JC. (1981). Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet, 2(8256):1137-1139
8. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. (1985). Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet, 1(8433):865.
9. Stead RJ, Hodson ME, Batten JC. (1987). Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest, 81(3):272-279
10. Wall MA, Terry AB, Eisenberg J, McNamara M, Cohen R. (1983). Inhaled antibiotics in cystic fibrosis. Lancet, 1(8337):1325.
11. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. (1997). Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol, 23(4):249-260
12. Barclay ML, Begg EJ. (1994). Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev, 13(4):207-234
13. Moore RD, Lietman PS, Smith CR. (1987). Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis, 155(1):93-99
14. Pritchard JN. (2001). The influence of lung deposition on clinical response. J Aerosol Med-Dep Clear Effects Lung, 14:S19-26.
15. Courrier HM, Butz N, Vandamme TF. (2002). Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst, 19(4-5):425-498
16. Islam N, Gladki E. (2008). Dry powder inhalers (DPIs)-A review of device reliability and innovation. Int J Pharm, 360(1-2):1-11.
17. Smith IJ, Parry-Billings M. (2003). The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther, 16(2):79-95.
18. Young PM, Traini D, Coates M, Chan HK. (2007). Recent advances in understanding the influence of compositeformulation properties on the performance of dry powder inhalers. Phys B Condens Matter, 394(2):315-319
19. Zeng XM, Martin GP, Marriott C. (1995). The controlled delivery of drugs to the lung. Int. J. Pharm., 124(2):149-164
20. Yamamoto A, Yamada K, Muramatsu H, Nishinaka A, Okumura S, Okada N, et al. (2004). Control of pulmonary absorption of water-soluble compounds by various viscous vehicles. Int J Pharm, 282(1-2):141-149
21. Brook, I. (2002). The prophylaxis and treatment of anthrax. Int J Antimicrob Agents, 20(5):320-325
22. Performance Standards for Antimicrobial Disk Susceptibility Testing (approved standard, 10th Edition) (1991). NJ: Clinical and Laboratory Standards Institute (CLSI)
23. Salama R, Hoe S, Chan HK, Traini D, Young PM. (2008). Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: Influence of polymer concentration on physical and in vitro characteristics. Eur J Pharm Biopharm, 69(2):486-495
24. Adi H, Young PM, Chan HK, Stewart P, Agus H, Traini D. (2008). Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci, 97(8):3356-3366
25. Rodwell DE, Kelly CM, DeMerlis CC, Schoneker, DR, Borzelleca JF. (2003). Effects of polyvinyl alcohol administered in the diet to rats on fertility, early embryonic development, growth and development. Food Chem Toxicol, 41(5):729-737
26. Salama R, Ladd L, Chan HK, Traini D, Young PM. (2009). Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles. AAPSJ. DOI: 10.1208/S12248-009-9125-0
27. Salama R, Traini D, Chan HK, Young PM. (2008). Preparation and characterisation of controlled release co-spray dried drug- polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm, In press.
28. Widdicombe JH. (2002). Regulation of the depth and composition of airway surface liquid. J Anatomy, 201(4):313-318
29. Franz TJ. (1975). Percutaneous absorption-relevance of invitro data. J Investig Dermatol, 64(3):190-195
30. Varanda F, de Melo MJP, Caco AI, Dohrn R, Makrydaki FA, Voutsas E, et al. (2006). Solubility of antibiotics in different solvents. 1. Hydrochloride forms of tetracycline, moxifloxacin, and ciprofloxacin. Ind Eng Chem Res, 45(18):6368-6374
31. Bogardus JB, Blackwood RK. (1979a). Dissolution rates of doxycycline free base and hydrochloride salts. J Pharm Sci, 68(9):1183-1184
32. Bogardus JB, Blackwood RK. (1979b). Solubility of doxycycline in aqueous-solution. J Pharm Sci, 68(2):188-194
33. AbuBaker O. (2006). Polyvinyl alcohol. In: Rowe RC, Sheskey PJ, Owen SC, eds. Handbook of pharmaceutical excipients, vol.5th ed. London: Pharmaceutical Press, 592-593
34. Sweeney LG, Wang ZL, Loebenberg R, Wong JP, Lange CF, Finlay WH. (2005). Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm, 305(1-2): 180-185
35. Zhanel GG, Ennis K, Vercaigne L. (2002). A critical review of the fluoroquinolones: Focus on respiratory tract infections. Drugs, 62(6):944.